Cargando…
A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients
Background: Pyroptosis is a form of programmed cell death accompanied by specific inflammatory and immune responses, and it is closely related to the occurrence and progression of various cancers. However, the roles of pyroptosis-related genes (PRGs) in the prognosis, treatment response, and tumor m...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648539/ https://www.ncbi.nlm.nih.gov/pubmed/36386841 http://dx.doi.org/10.3389/fgene.2022.1006151 |
_version_ | 1784827603546275840 |
---|---|
author | Xiao, Xi Li, Jianpeng Wan, Shun Wu, Mingzhe Li, Zonglin Tian, Junqiang Mi, Jun |
author_facet | Xiao, Xi Li, Jianpeng Wan, Shun Wu, Mingzhe Li, Zonglin Tian, Junqiang Mi, Jun |
author_sort | Xiao, Xi |
collection | PubMed |
description | Background: Pyroptosis is a form of programmed cell death accompanied by specific inflammatory and immune responses, and it is closely related to the occurrence and progression of various cancers. However, the roles of pyroptosis-related genes (PRGs) in the prognosis, treatment response, and tumor microenvironment (TME) of prostate cancer (PCa) remain to be investigated. Methods: The mRNA expression data and clinical information of PCa patients were obtained from the Cancer Genome Atlas database (TCGA) and the cBioPortal for Cancer Genomics website, and the 52 PRGs were obtained from the published papers. The univariate, multivariate, and LASSO Cox regression algorithms were used to obtain prognostic hub PRGs. Meanwhile, qRT-PCR was used to validate the expression of hub genes between PCa lines and normal prostate epithelial cell lines. We then constructed and validated a risk model associated with the patient’s disease-free survival (DFS). Finally, the relationships between risk score and clinicopathological characteristics, tumor immune microenvironment, and drug treatment response of PCa were systematically analyzed. Results: A prognostic risk model was constructed with 6 hub PRGs (CHMP4C, GSDMB, NOD2, PLCG1, CYCS, GPX4), and patients were divided into high and low-risk groups by median risk score. The risk score was confirmed to be an independent prognostic factor for PCa in both the training and external validation sets. Patients in the high-risk group had a worse prognosis than those in the low-risk group, and they had more increased somatic mutations, higher immune cell infiltration and higher expression of immune checkpoint-related genes. Moreover, they were more sensitive to cell cycle-related chemotherapeutic drugs and might be more responsive to immunotherapy. Conclusion: In our study, pyroptosis played a significant role in the management of the prognosis and tumor microenvironment of PCa. Meanwhile, the established model might help to develop more effective individual treatment strategies. |
format | Online Article Text |
id | pubmed-9648539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96485392022-11-15 A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients Xiao, Xi Li, Jianpeng Wan, Shun Wu, Mingzhe Li, Zonglin Tian, Junqiang Mi, Jun Front Genet Genetics Background: Pyroptosis is a form of programmed cell death accompanied by specific inflammatory and immune responses, and it is closely related to the occurrence and progression of various cancers. However, the roles of pyroptosis-related genes (PRGs) in the prognosis, treatment response, and tumor microenvironment (TME) of prostate cancer (PCa) remain to be investigated. Methods: The mRNA expression data and clinical information of PCa patients were obtained from the Cancer Genome Atlas database (TCGA) and the cBioPortal for Cancer Genomics website, and the 52 PRGs were obtained from the published papers. The univariate, multivariate, and LASSO Cox regression algorithms were used to obtain prognostic hub PRGs. Meanwhile, qRT-PCR was used to validate the expression of hub genes between PCa lines and normal prostate epithelial cell lines. We then constructed and validated a risk model associated with the patient’s disease-free survival (DFS). Finally, the relationships between risk score and clinicopathological characteristics, tumor immune microenvironment, and drug treatment response of PCa were systematically analyzed. Results: A prognostic risk model was constructed with 6 hub PRGs (CHMP4C, GSDMB, NOD2, PLCG1, CYCS, GPX4), and patients were divided into high and low-risk groups by median risk score. The risk score was confirmed to be an independent prognostic factor for PCa in both the training and external validation sets. Patients in the high-risk group had a worse prognosis than those in the low-risk group, and they had more increased somatic mutations, higher immune cell infiltration and higher expression of immune checkpoint-related genes. Moreover, they were more sensitive to cell cycle-related chemotherapeutic drugs and might be more responsive to immunotherapy. Conclusion: In our study, pyroptosis played a significant role in the management of the prognosis and tumor microenvironment of PCa. Meanwhile, the established model might help to develop more effective individual treatment strategies. Frontiers Media S.A. 2022-10-27 /pmc/articles/PMC9648539/ /pubmed/36386841 http://dx.doi.org/10.3389/fgene.2022.1006151 Text en Copyright © 2022 Xiao, Li, Wan, Wu, Li, Tian and Mi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Xiao, Xi Li, Jianpeng Wan, Shun Wu, Mingzhe Li, Zonglin Tian, Junqiang Mi, Jun A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients |
title | A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients |
title_full | A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients |
title_fullStr | A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients |
title_full_unstemmed | A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients |
title_short | A novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients |
title_sort | novel signature based on pyroptosis-related genes for predicting prognosis and treatment response in prostate cancer patients |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9648539/ https://www.ncbi.nlm.nih.gov/pubmed/36386841 http://dx.doi.org/10.3389/fgene.2022.1006151 |
work_keys_str_mv | AT xiaoxi anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT lijianpeng anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT wanshun anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT wumingzhe anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT lizonglin anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT tianjunqiang anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT mijun anovelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT xiaoxi novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT lijianpeng novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT wanshun novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT wumingzhe novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT lizonglin novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT tianjunqiang novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients AT mijun novelsignaturebasedonpyroptosisrelatedgenesforpredictingprognosisandtreatmentresponseinprostatecancerpatients |